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Abstract: By endolymphatic injection of radioisotope 131I.Lipiodol,
so.called endolymphatic radiotherapy, we treated 10 cases with malig-
nant lymphoma and found a marked tumor reduction to normal size
in all the 10 cases we tried. It seems that this method is one of the
most effective therapeutic methods for malignant lymphoma, espe.
cially invading into the retroperitoneal lymph nodes.
It was FISCHER and ZIMMERMAN (1) who first suggested a possibility of
applying lymphography for the treatment, and WALLACE et al, (2, 3) attempted
first to inject therapeutic materials into the lymph vessels for treatment.
Subsequently, there appeared many reports by CHIAPPA et al, (4-7) who
treated malignant lymphoma and metastatic lymph nodes by injecting 1311_
Lipiodol into the lymphatics, the so-called endolym,phatic radiotherapy.
Simultaneously ARIEL (8, 9), SEITZMAN (10), BETOULIERES et al, (11), LIEBNER
(12), zum WINKEL et al, (13) have reported the efficacy of this therapeutic
method on malignant lymphoma. Despite these clinical studies carried out
using endolymphatic isotopes, there is still controversy on the importance and
limitations of this method in the treatment of malignant lymphoma. In addi-
tion, there is as yet no report on study concerning this therapy in Japan.
In our experimental study on dogs, we reported that this method had
little side-effect and it showed the irradiation effect selectively on lymph
nodes (14). Since then we have applied this therapeutic method to patients
with malignant lymphoma and observed a marked reduction of tumors in all
the cases we treated. Here we present our clinical results.
PATIENTS AND METHODS
The patients on whom endolymphatic radiotherapy was attempted were
10 cases as shown in Table I ; consisted of 3 cases of Hodgkin's disease, 4 reti-
culum cell sarcomas, one lymphosarcoma and two chronic lymphatic leukemia.
The isotope used was intralymphatic injection iodinated triolein 1311 in
Lipiodol U. -F. (a product of the Radiochemical Center, England and abbre.
viated as 131I.Lipiodol in this report). To each case 4.5 ml 131I-Lipiodol con·
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TABLE 1 PATIENTS TREATED WITH ENDOL YMPHA TIC RADIOTHERAPY
Survival time
Case Sex Age Histological Dead or After the onset After 1311diagnosis* alive** administration
Years Months Years Months
1 M 55 RCS dead 2 1 1 3
2 M 33 CLL alive 5 10 3 4
3 M 39 RCS dead 10 7
4 M 51 Hodgkin dead 9 9
5 M 49 Hodgkin alive 5 2 8
6 M 28 Hodgkin alive 4 9 2 6
7 M 42 CLL alive 3 1 2 II
8 M 68 RCS alive 1 II 1 3
9 M 68 LS dead 2 1
10 M 24 RCS dead 6
* RCS: Reticulum Cell Sarcoma
CLL: Chronic Lymphatic Leukemia
LS: Lymphosarcoma
** on the 31 March, 1973
taining specific radioactivity of 10 mCi/ml was used. The total volume of 1311.Lipiodol on each side was adjusted before injection to 7-10 ml by mixing withLipiodol Ultrafluide not containing isotope.
Following the method of KINMONTH, the mixture of 0.5 ml patent blue and
an equal volume of 1-2% xylocaine was subcutaneously injected on the dorsum
of both feet, then incision was made for 1. 5-2 cm along the visible lymphatic
stained blue to expose the lymph vessel, needle was inserted into the lymphatic
and physiological saline was injected through the needle. After confirming
the saline flow into the lymph vessel, isotope was simultaneously injectedbilaterally into the exposed dorsal lymph vessels.
In order to limit the uptake of free 1311 by the thyroid, 10 ml (50 mg)iodinated sodium solution was given orally to the patient the night before theinjection.
Immediately thereafter and 24 hours after the injection periodically atintervals of about one week, abdominal and chest X.rays (anterior.posterior,lateral and oblique pictures) were taken. The plane scanning, linear scanning,
and the scintillation camera were also used to detect the organ distribution of
the isotope. In addition, to check the excretion of 1311 into feces and urine,the amounts of 1311 excreted into urine and feces were measured every twodays for two weeks.
For determining of therapeutic effects, the size of lymph node was
measured by planimetery on the lymphograms taken periodically after theisotope injection, and was calculated by the degree of shrinkage expressed in
terms of percentage by the following formula: A~B_x100 (where A: the total
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area of the lymph node before the isotope injection, B: the total area of lymph
node at given days after the injection); we studied the efficacy from the so-
called tumor shrinkage curves, and also took the improvement of subjective
symptoms and changes of humoral factors into consideration.
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RESULTS
1. Effect on lymphoma with endolymphatic radiotherapy
Fig. 1 shows the results of endolymphatic radiotherapy conducted on the
patients being determined by the
tumor shrinkage. This was mea-
sured with lapse of time and was
expressed in percentage, indicat-
ing a marked shrinkage of tumors
in all the cases treated; the
shrinkage of 20-50%, (35% in
average) 2 weeks later and 50%
in average one month later. Two
representative cases are describ-
ed as follows.
Case 1. A 55-year old fe·
male with main complaint of
systemic lymph node swelling.
case 1 Marked lymph node swellings
were observed at each side of
neck, the left clavicular fossa,
and especially the right inguinal
Days after 13lJ administration . h' f" B
regIOn reac mg 1st-sIze. y
Fig,!. The tumor shrinkage curves of patients b' h' d' d
treated with endolymphatic radiotherapy. IOPSY t IS was lagnose as
reticulum cell sarcoma. After
endolymphatic injection of 35mCi 131I-Lipiodol from the dorsum of both feet,
on the third day the right inguinal lymph node, which was as big as a fist,
was somewhat softened and began to shrink, by one week it became clearly
smaller, and within two weeks it grew as small as the tip of thumb. Fig. 2
and Fig. 3 illustrate the lymphograms taken 24 hours and one month after the
131I-Lipiodol injection respectively. As shown in these lymphograms the
swollen inguinal and the retroperitoneal lymph nodes are markedly reduced
in sizes. Studying the case by the lymph node shrinkage curves, the rate of
shrinkage is 50% by two weeks, and 60% by three weeks as shown in Fig. 1.
By the scanning (Fig. 4) and the scintillation camera (Fig. 5) it is obvious that
131I-Lipiodol has been distributed homogeneously to lymph nodes. By the
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Fig. 2. Lymphogram' taken 24 hours after
administration of 131I·Lipiodol (Case I)
Fig. 3. Lymphogram taken one month later
(Case I). Note remarkable shrinkage of lymph
nodes.
linear scanning conducted at intervals of 2 hours and one week after 131I
Lipiodol injection as shown in Fig. 6, the isotope is distributed quite densely
and selectively in the inguinal and retroperitoneal lymph nodes. And it was
demonstrated that the isotope is retained in the lymph nodes over a long
period of time as observed in animal experiments. 131I-distribution in the
lung is clearly observable, but it was diminished markedly and quite rapidly.
In thyroid gland its distribution was not detected by the linear or plane
scanning. Treatment with Bleomycin was started on this patient 3 weeks after
131J·Lipiodol injection. The superficial lymph nodes became hardly detect-
able, the retroperitoneal lymphogram returned practically normal, general
conditions were also improved, and she was discharged after 3 months of
treatment. There could be observed no marked change of peripheral blood
picture and bone marrow picture, nor was there any abnormality of the
thoracic X-ray picture and functions of liver and thyroid gland.
Case 2. A 33-year old male, with chief complaint of bilateral swelling
of the neck. There were somewhat hard lymph nodes of a pea to a hen's egg
size palpable bilaterally under the jaw, on the both sides of neck, in the
clavicular fossa and in the inguinal region. There was no fusion nor severe
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Fig. 4. Scintigram after administration of
13lJ-Lipiodol (case 1). Note retention of the
isotope throughout the pelvic and periaortic
lymph nodes
Fig. 5. Scinticamera of Case 1. upper:
chest. middle: abdomen. lower: in-
guinal
Fig. 6. Linear scan of Case 1.
pain. By biopsy and other laboratory
findings this case was diagnosed as chronic
lymphatic leukemia. The retroperitoneal
lymph nodes revealed a moderate swelling
presenting the picture characteristic of
malignant lymphoma by the lymphogram
with Lipiodol Ultrafluide not containing
1311. The Iymphograms taken periodically
did not show any clear-cut shrinkage even
at the termination of Bleomycin (15mgjday,
twice a week to the total of 300 mg).
Therefore, the endolymphatic therapy of
131I-Lipiodol was commenced, and pursued
the size of lymphoma by the X-ray pictures
taken with lapse of time. Three weeks
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later the shrinkage was over 50% and one month later over 60%, clearly
showing the improvement as in Case 1 (Fig. l). The uptake of 1311 into the
lymph nodes is extremely marked by scintigram or scinticamera. By the linear
scanning conducted with lapse of time the 131I-distribution in. the inguinal
and retroperitoneal lymph nodes is marked.
2. The excretion of 13 11 into urine and feces in the cases receiving endolymphatic
radiotherapy.
Figs. 7 and 8 show the amounts of 131I excreted into urine and feces
respectively. The excreted amounts vary considerably with cases; in general
2 4 6 8 /0 /2 /4-
Days after 1311 administration
Fig. 8. Excretion of 1311 into feces in the
patients given endolymphatic radiotherapy
2 4 6 8 ~ n u
Days after 1311 administration
Fig. 7, Excretion of 13 11 into urine in
the patients given endolymphatic radio-
therapy
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the excretion into urine for two weeks was 5 to 40% showing an inverse
relation to the swelling of the inguinal and retroperitoneal lymph nodes.
Excretion into feces was under I % in all the cases.
DISCUSSION
Advantages of the 131I-Lipiodol injection into the lymphatics, so-called
endolymphatic radiotherapy, can be pointed out as follows; I) the treatment
can be accomplished by a single injection into the lymph vessel and, if
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necessary, repeated injections can be done. 2) By lymphograms, scintiscann-
ing, and scinticamera it is possible to observe the 131I-distribution in the
lymph nodes. And by taking roentgenograms with lapse of time we can
obtain the lymph node shrinkage curves, by which the shrinkage effect can
be determined objectively. 3; As the radiation range of p-emitter from 13 11
is about 2 rom, a strong radioactivity is directly gathered onto the pathologic
focus, although it hardly gives any injurious effect on the organs around the
pathological lymph nodes. 4) Other than a transient or a slight lYmphocyto-
penia (15) there is no inhibitory effect at all on the hematopoietic organs in-
cluding the bone marrow.
It has been said that in the endolymphatic injection of 131I-Lipiodol from
the dorsum of feet the retroperitoenal lymph nodes receive 200-800 rads
(Siegel), 333-1, 000 rads (Picard), 700 rads in average (Dargent, Romeiu) per
1 mCi of 131I-Lipiodol (13). Therefore, for the cases with malignant lym-
phoma showing the lymph nodes swelling in the inguinal, iliac and retro-
peritoneal regions this method seems to be of the first choice. Also in our
10 cases the lymph node shrinkage was marked. Especially, Case 2, who was
treated with Bleomycin 2 months prior to the 131I-Lipiodol injection, showed
no clear-cut shrinkage of lymph nodes. When the 131I-Lipiodol treatment was
given, the shrinkage of lymph nodes was observed in about the same degree as
with the other cases, and this case suggested a possibility of the shrinkage
effect by 13lJ-Lipiodol even in the malignant lymphoma whereby Bleomycin
alone does not induce the shrinkage.
As for side-effects, oil embolism of the lung by the contrast medium has
been pointed out, but it is extremely rare to see any case raising clinical
problems. 131 I, that has entered into the lung and has been distributed, is
excreted more rapidly than in lymph nodes and cause little irradiation damage.
By histological observations of the lung in animal experiments, likewise, no
fibrosis nor any other injurious effects could be seen (14). And by the X-ray
pictures there were no findings suggestive of fibrosis and other abnormalities.
It is also reported that in 16% of the patients treated amenorrhea occurred, two
cases showed disorders of liver function due to 131 r-Lipiodol, and hemolytic
anemia occurred in one case (7). We did not, however, encounter such side
effects in our cases. As obvious from the results of the 10 cases whom we
treated, endolymphatic radiotherapy seems to be an extremely useful therapy
for malignant lymphoma with the involvement of retroperitoneal lymph nodes
as an ajunct of ordinary radiotherapy and chemotherapy.
Acknowledgement: The authors wish to thank Prof. K. HIRAKI for valuable advice and for
reviewing the manuscript.
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